drugset
drugset / Trial / NCT05109611

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection

NCT05109611 ↗

Phase 3 Terminated 1389 enrolled Sanotize Research and Development corp.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

A multicenter, randomized, double-blinded, placebo-controlled, phase 3 clinical efficacy study evaluating nitric oxide nasal spray (NONS) as prevention for treatment of individuals at risk of exposure to COVID-19 infection.

Timeline

Start
2021-11-20
Primary completion
2024-01-30
Completion
2024-04-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nitric Oxide Other / unclassified 0.5 ml Intranasal

Indications

COVID-19